Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

StockBeat - J&J Falls as Justice Department Launches Probe Into Talc Cancer Claims

Published 13/07/2019, 03:08 am
© Reuters.
DJI
-
JNJ
-

Investing.com – Johnson & Johnson plunged Friday as the Justice Department reportedly launched a criminal investigation into whether the company lied about the possible cancer risks of its talcum powder.

Investing.com – Johnson & Johnson plunged Friday as the Justice Department reportedly launched a criminal investigation into whether the company lied about the possible cancer risks of its talcum powder.

A grand jury in Washington is examining documents related to what company officials knew about any carcinogens in their products, Bloomberg reported. Johnson & Johnson (NYSE:JNJ) fell more than 4%.

The company said in a statement that it is cooperating with the previously announced DOJ investigation and that there are no new developments. It also reiterated its previous denials of wrongdoing.

A grand jury in Washington is examining documents related to what company officials knew about any carcinogens in their products, Bloomberg reported. Johnson & Johnson (NYSE:JNJ) fell nearly 5%. That was enough to subtract 46 points from the Dow on an otherwise bullish day.

The company said in a statement that it is cooperating with the previously announced DOJ investigation and that there are no new developments. It also reiterated its previous denials of wrongdoing.

With Johnson & Johnson already facing more than 13,000 talc-related lawsuits nationwide, the probe by Justice will do little ease investor fears the healthcare conglomerate could be on hook to pay out hefty settlements to claimants, resulting in massive liabilities.

With Johnson & Johnson (NYSE:JNJ) already facing more than 13,000 talc-related lawsuits nationwide, the Justice Department probe will do little to ease investor fears the healthcare conglomerate could be on the hook to pay out hefty settlements to claimants, resulting in massive liabilities.

Last month, a California jury ruled in favor of a plaintiff who claimed her use of the company’s talc powder caused cancer. A month earlier in May, the company was ordered to pay out $300 million in punitive damages to women who also claimed the company’s talc powder caused asbestos-linked cancer.

Last month, a California jury ruled in favor of a plaintiff who claimed her use of the company’s talc powder caused a rare cancer. In May, the company was ordered to pay out $300 million in punitive damages to women who also claimed the company’s talc powder caused asbestos-linked cancer.

Reuters said last year that an examination of internal company memos and other documents found the Johnson & Johnson was aware of the presence of asbestos in its products from as early as 1971 but failed to disclose that fact to regulators or to the general public.

Reuters said last year that an examination of internal company memos and other documents found the Johnson & Johnson was aware of the presence of asbestos in its products from as early as 1971 but failed to disclose that fact to regulators or to the general public.

The company called the Reuters report “one-sided, false and inflammatory” and has continually denied its Baby Powder talc causes cancer, stressing that numerous studies and tests by regulators worldwide have shown that it is safe.

The company called the Reuters report “one-sided, false and inflammatory” and has continually denied its Baby Powder talc causes cancer, stressing that numerous studies and tests by regulators worldwide have shown that it is safe.

While Baby Powder only makes up a small portion of total revenue, it is a core brand.

While Baby Powder only makes up a small portion of total revenue, it is a core brand.

Johnson and Johnson is up about 4.4% year to date. The company is set to report quarterly performance on July 16.

Johnson and Johnson is up about 4% this year. The company is set to report quarterly performance on July 16.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.